<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Synthetic cannabinoids: Acute intoxication
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Synthetic cannabinoids: Acute intoxication
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Synthetic cannabinoids: Acute intoxication
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            George Sam Wang, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michele M Burns, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert G Hendrickson, MD, FACMT, FAACT
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Ganetsky, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 20, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1084269930">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         This topic discusses the epidemiology, pharmacology, toxicity, clinical manifestations, and management of acute intoxication with synthetic cannabinoids will be discussed here.
        </p>
        <p>
         The clinical manifestations and management of toxicity from cannabis (marijuana), medical uses of cannabinoids, and the manifestations and treatment of cannabis use disorder are provided separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/97099.html" rel="external">
          "Cannabis (marijuana): Acute intoxication"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2815.html" rel="external">
          "Cancer pain management: Role of adjuvant analgesics (coanalgesics)", section on 'Cannabis and cannabinoids'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1690.html" rel="external">
          "Symptom management of multiple sclerosis in adults", section on 'Cannabinoids'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/85750.html" rel="external">
          "Assessment and management of nausea and vomiting in palliative care", section on 'Cannabinoids and cannabis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">
          "Overview of the management of epilepsy in adults", section on 'Alternative therapies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7797.html" rel="external">
          "Cannabis use and disorder: Epidemiology, pharmacology, comorbidities, and adverse effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7796.html" rel="external">
          "Cannabis use disorder: Clinical features, screening, diagnosis, and treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1084269936">
         <span class="h1">
          BACKGROUND
         </span>
         <span class="headingEndMark">
          —
         </span>
         Over 60 cannabinoids are found in natural marijuana and include delta-9 tetrahydrocannabinol (THC), the most psychoactive cannabinoid, cannabidiol (CBD), and cannabinol (CBN). Synthetic cannabinoids are chemically synthesized compounds and not naturally occurring cannabinoids. They may have been available in Europe as early as 2004, and were first reported in the United States in December 2008 [
         <a href="#rid1">
          1
         </a>
         ]. They are now classified as Class I controlled substances by the United States Drug Enforcement Administration and are illegal to possess, sell, and use [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         The synthetic compound is sold as the chemical itself, or added to herbs or other plants (eg,
         <em>
          Canavalia sp, Nymphaea sp, Pedicularis sp, Leonotis sp
         </em>
         ) to appear as a natural product and is typically marketed as "incense" or "herbal remedies." They are sold under various names including: "K2," "spice," "crazy monkey," "chill out," "spice diamond," "spice gold," "chill X" or by its chemical nomenclature (eg, AMB-FUBINACA, JWH-018, CP 47, and many others) [
         <a href="#rid1">
          1,3-7
         </a>
         ]. Adulteration of cannabis products with synthetic cannabinoids has been reported [
         <a href="#rid8">
          8
         </a>
         ]. A synthetic cannabinoid has also been discovered in counterfeit cannabidiol oil (hemp or CBD oil) which resulted in a poisoning outbreak in Utah [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Despite the term “cannabinoid”, most of the chemical structures of synthetic cannabinoids are not analogs of THC. The clinical effects can be similar to natural marijuana intoxication but may also result in more severe life-threatening symptoms. The chemical structures of synthetic cannabinoids consist of four building blocks: a core group (eg, indoles, indazoles), a tail group (eg, pentyl, 5F-pentyl, halogenation), a linker group (eg, carboxamide, methanone), and linked groups (eg, naphthyl, phenyl, valinate) [
         <a href="#rid10">
          10,11
         </a>
         ]. The structures of these building blocks determine nomenclature and are constantly being changed to avoid regulatory oversight [
         <a href="#rid10">
          10-12
         </a>
         ]. Such changes may introduce additional, and often unpredictable, toxic and clinical effects.
        </p>
        <p class="headingAnchor" id="H1084269943">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Synthetic cannabinoids are recreational drugs commonly misused in the United States and Europe [
         <a href="#rid13">
          13-15
         </a>
         ]. Synthetic cannabinoids can cause significant toxicity, including fatalities, and continue to be associated with intermittent outbreaks of individuals warranting emergency department care [
         <a href="#rid16">
          16-23
         </a>
         ].
        </p>
        <p>
         Synthetic cannabinoids represent a large portion of novel psychoactive substances used around the world. In 2014, the European Drug Emergencies Network reported synthetic cannabinoids accounted for only 3 percent of agents, which increased to 72 percent in 2019 [
         <a href="#rid24">
          24
         </a>
         ]. In 2021, of the 880 new psychoactive substances monitored by the European Monitoring Centre for Drugs and Drug Addiction, more than 220 are synthetic cannabinoids [
         <a href="#rid13">
          13,25
         </a>
         ].
        </p>
        <p>
         Individuals who misuse synthetic cannabinoids are typically adult males [
         <a href="#rid16">
          16,23
         </a>
         ]. Among surveyed United States adolescents, 1.4 percent self-report regular use, typically as part of polysubstance misuse [
         <a href="#rid26">
          26
         </a>
         ]. In one multicenter observational study of consultations performed by medical toxicologists, adolescents (13 to 18 years of age) accounted for about one quarter of patients presenting to hospitals and clinics for acute synthetic cannabinoid poisoning [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         From 2016 to 2019, increased cannabis legalization across the United States was associated with a decline in synthetic cannabinoid cases reported to United States regional poison centers [
         <a href="#rid23">
          23
         </a>
         ]. The decline was greatest in states with permissive cannabis laws.
        </p>
        <p class="headingAnchor" id="H1084269950">
         <span class="h1">
          TOXICITY AND PHARMACOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many physiologic effects of synthetic cannabinoids are similar to cannabis (marijuana) and include tachycardia, conjunctival injection (red eyes), increased appetite, nystagmus, ataxia, and slurred speech. However, compared with cannabis, synthetic cannabinoids have a greater potential for serious neuropsychiatric toxicity including hallucinations, delirium, and psychosis [
         <a href="#rid16">
          16,24,28-33
         </a>
         ]. Furthermore, life-threatening toxicity caused by severe agitation or seizures is more characteristic of toxicity from synthetic cannabinoids. (See
         <a class="medical medical_review" href="/z/d/html/97099.html" rel="external">
          "Cannabis (marijuana): Acute intoxication", section on 'Adolescents and adults'
         </a>
         .)
        </p>
        <p>
         Synthetic cannabinoids differ from naturally occurring cannabinoids in their potency and clinical effects. They are typically added to herbals or other hallucinogenic plants and smoked, but they also can be ingested or insufflated in pure form. Inhalation of burning incense adulterated with a synthetic cannabinoid compound has caused mass intoxication [
         <a href="#rid12">
          12
         </a>
         ]. They can be partial or full agonists at cannabinoid receptors, and various synthetic cannabinoids have a diversity of potency and clinical effects [
         <a href="#rid1">
          1,23,24,33-36
         </a>
         ]. They are metabolized mostly through oxidation and glucuronidation via liver cytochrome oxidase enzymes and excreted renally [
         <a href="#rid36">
          36
         </a>
         ]. Some compounds, such as the naphthoylindoles, have reported active metabolites [
         <a href="#rid37">
          37
         </a>
         ]. It is difficult to report specific toxic doses because the compounds and content change constantly [
         <a href="#rid20">
          20
         </a>
         ]. Toxicity depends upon the amount used and the specific compound.
        </p>
        <p>
         Synthetic cannabinoids are a chemically heterogeneic group of compounds. Similar to natural cannabinoids, they act as agonists at cannabinoid (CB) receptors (mostly CB1), which causes psychoactive effects [
         <a href="#rid7">
          7,20
         </a>
         ]. Other receptor and enzyme involvement has yet to be elucidated but may include serotonin and N-methyl-D-aspartate (NMDA) receptors and monoamine oxidase inhibition [
         <a href="#rid3">
          3,6,38
         </a>
         ]. Although they act on similar receptors, synthetic cannabinoids are often more potent agonists, with reports of potencies ranging from 2 to 800 times greater than delta-9 tetrahydrocannabinol [
         <a href="#rid3">
          3
         </a>
         ]. The herbal product or plant that serves as the vehicle for synthetic cannabinoid delivery may also have hallucinogenic properties, or may contain other contaminants (such as caffeine, nicotine, and
         <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">
          tramadol
         </a>
         ) that can contribute to clinical effects and toxicity [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         As of 2021, over 240 known synthetic cannabinoids have been manufactured by illicit drug laboratories and there is significant potential for novel compounds to appear in the future [
         <a href="#rid10">
          10
         </a>
         ]. Identified synthetic cannabinoids fall into many major structural groups [
         <a href="#rid1">
          1,3-7,10,12,39-41
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Classical cannabinoids (ie, analogues of delta-9 tetrahydrocannabinol), derived from a dibenzopyran ring (eg, HU-210,
         <a class="drug drug_general" data-topicid="9995" href="/z/d/drug information/9995.html" rel="external">
          nabilone
         </a>
         , or
         <a class="drug drug_general" data-topicid="9394" href="/z/d/drug information/9394.html" rel="external">
          dronabinol
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Naphthoylindoles (JWH-018, 073)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Naphthylmethylindoles
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Naphthoylpyrroles
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Naphthylmethylindenes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Phenylacetylindoles (JWH-0259)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cyclohexylphenols (CP 47)
        </p>
        <p>
        </p>
        <p>
         An additional category includes miscellaneous compounds, including fatty acid amides such as oleamide, which have a similar structure to endogenous cannabinoids such as anandamide [
         <a href="#rid42">
          42
         </a>
         ]. They have various industrial uses (anti-slip agent, plastics), but their status as an abuse agent is uncertain.
        </p>
        <p class="headingAnchor" id="H1084269958">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Synthetic cannabinoids have a wide spectrum of clinical effects which occur soon after inhalation or insufflation and can last several hours to days, depending upon the compound and potency [
         <a href="#rid16">
          16,28-32,43
         </a>
         ]. Signs of intoxication vary by the specific compound.
        </p>
        <p>
         Clinical effects of some agents can share many characteristics of cannabis (marijuana) intoxication, including agitation, tachycardia, conjunctival injection, nystagmus, vomiting, ataxia, sedation, and slurred speech. However, unlike cannabis, synthetic cannabinoids have significant potential to cause serious and life-threatening toxicity [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
         The most common clinical effects based upon approximately 2000 reports of single agent exposure to regional poison control centers in 2010 consist of tachycardia, agitation, and vomiting [
         <a href="#rid16">
          16
         </a>
         ]. For these mild to moderate symptoms, duration is typically less than eight hours.
        </p>
        <p>
         However, synthetic cannabinoids have significant potential to cause more serious toxicity. As an example, in a report from a multicenter, hospital-based registry of consultations performed by medical toxicologists, the frequency of signs or symptoms after single agent exposure to synthetic cannabinoids in 277 cases from 2010 to 2015 was as follows [
         <a href="#rid27">
          27
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Agitation, coma, toxic psychosis, or other nervous system finding (eg, seizures, hallucinations) - 66 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bradycardia, tachycardia, or other cardiovascular finding - 17 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rhabdomyolysis - 6 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Respiratory depression - 5 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute kidney injury - 4 percent
        </p>
        <p>
        </p>
        <p>
         Neurologic findings such as severe psychomotor agitation, psychosis, seizures, hallucinations, delirium, dystonia, and paranoia have been highlighted in several case reports and case series [
         <a href="#rid16">
          16,28-33,45-47
         </a>
         ]. In a prospective, observational study of adolescents undergoing specialty consultation for synthetic cannabinoid or cannabis exposure, patients with synthetic cannabinoid intoxication were more likely to demonstrate neuropsychiatric morbidity, such as coma and seizures, than individuals with cannabis intoxication [
         <a href="#rid44">
          44
         </a>
         ]. Marked motor activity from agitation or seizures may also cause hyperthermia and rhabdomyolysis. Deaths have been reported, including sudden death after first-time use of inhaled synthetic cannabinoids in a 17-year-old adolescent [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         Synthetic cannabinoid intoxication in young children occurs rarely but has the potential for severe toxicity. For example, a three-year-old child developed coma, nystagmus, hypotonia, apnea, and bradycardia necessitating rapid sequence intubation, chest compressions, intravenous
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         , and continuous vasopressor infusion after unsupervised exposure to 5-fluoro-PICA-3,3-dimethylbutanoic acid [
         <a href="#rid48">
          48
         </a>
         ]. Identification of synthetic cannabinoid exposure was not disclosed in this case and required involvement of law enforcement and specialized laboratory techniques to make the diagnosis.
        </p>
        <p>
         Additional manifestations of synthetic cannabinoid intoxication that vary from earlier reports have been described. In a report of mass exposure of 33 adults to burning incense containing methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (AMB-FUBINACA) with the street name AK-47 24 Karat Gold, intoxication was marked by lethargy, blank staring, "zombie-like" groaning, and slow mechanical movements of the arms and legs that resolved in &lt;12 hours after exposure ceased [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         Synthetic cannabinoids have also been associated with ischemic stroke, subarachnoid hemorrhage, chest pain, and myocardial ischemia and infarction in adolescents and young adults without risk factors for these events [
         <a href="#rid49">
          49-53
         </a>
         ]. In addition, an outbreak of reversible acute kidney injury occurred following regional use of a "blueberry spice" synthetic cannabinoid [
         <a href="#rid54">
          54-57
         </a>
         ]. It is unclear whether toxicity was due to the synthetic cannabinoid or an adulterant.
        </p>
        <p>
         Coagulopathy and serious bleeding after synthetic cannabinoid use has occurred in several regions of the United States from adulteration with a long-acting anticoagulant rodenticide. (See
         <a class="local">
          'Life-threatening coagulopathy (brodifacoum adulteration)'
         </a>
         below.)
        </p>
        <p>
         Because synthetic cannabinoids are frequently inhaled in a manner similar to cannabis (marijuana), they have the potential to cause chest pain due to acute exacerbations of asthma, pneumothorax, or pneumomediastinum. (See
         <a class="medical medical_review" href="/z/d/html/97099.html" rel="external">
          "Cannabis (marijuana): Acute intoxication", section on 'Adolescents and adults'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H252303046">
         <span class="h1">
          ANCILLARY STUDIES
         </span>
        </p>
        <p class="headingAnchor" id="H3016795335">
         <span class="h2">
          Patient with mild to moderate intoxication
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most mild or moderate intoxications, no ancillary studies are typically needed.
        </p>
        <p class="headingAnchor" id="H275150398">
         <span class="h2">
          Patient with other manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Additional testing may also be indicated based upon clinical features as follows:
        </p>
        <p class="headingAnchor" id="H3448174958">
         <span class="h3">
          Agitation or seizure
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with marked agitation or seizures should have prompt measurement of blood glucose. Because of the risk for rhabdomyolysis, lactic acidosis, stroke, intracranial hemorrhage, and acute kidney injury, patients with marked agitation or seizures warrant the following studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum electrolytes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blood urea nitrogen and creatinine
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Creatine kinase
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Venous blood gas
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum lactate
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum ethanol concentration
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete blood count with platelets
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rapid urine dip for blood and, if positive, urine for myoglobin
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rapid urine drug screen (to evaluate for co-exposure to other drugs of abuse)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oxygen saturation by pulse oximetry
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         12-lead electrocardiogram and continuous ECG monitoring
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urine pregnancy test (post-menarcheal females)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neuroimaging (patients with seizures)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H859937753">
         <span class="h3">
          Chest pain
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with chest pain suggestive of myocardial ischemia or infarction warrant a 12-lead electrocardiogram and cardiac biomarkers (eg, troponins). (See
         <a class="medical medical_review" href="/z/d/html/86.html" rel="external">
          "Troponin testing: Clinical use", section on 'Diagnosis of acute MI'
         </a>
         .)
        </p>
        <p>
         Chest radiograph or ultrasound may assist in the diagnosis of stable patients with chest pain indicative of a spontaneous pneumothorax. However, patients with signs of a tension pneumothorax should undergo decompression prior to chest radiography. Bedside ultrasound may assist with rapid diagnosis of pneumothorax in these unstable patients. (See
         <a class="medical medical_review" href="/z/d/html/6706.html" rel="external">
          "Pneumothorax in adults: Epidemiology and etiology", section on 'Epidemiology'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14888.html" rel="external">
          "Bedside pleural ultrasonography: Equipment, technique, and the identification of pleural effusion and pneumothorax"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3430673076">
         <span class="h3">
          Clinically significant bleeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with a history of recent synthetic cannabinoid use and unexplained bleeding should undergo testing of prothrombin time (PT), international normalized ratio (INR), and activated partial thromboplastin time (aPTT) to assess for coagulopathy secondary to possible brodifacoum adulteration [
         <a href="#rid58">
          58
         </a>
         ]. Coagulopathy from brodifacoum poisoning is characterized by prolongation of all three tests. (See
         <a class="local">
          'Life-threatening coagulopathy (brodifacoum adulteration)'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         In addition, patients should undergo the following tests:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Complete blood count with differential
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Type and screen for blood products or, if significant bleeding, type and cross match
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Urine dipstick for blood
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Plasma fibrinogen and serum fibrin degradation products
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Stool for guaiac
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other laboratory or imaging studies may also be indicated depending upon the specific sites of bleeding (eg, electrolytes, blood urea nitrogen, serum creatinine, and ultrasound or computed tomography [CT] of the abdomen for major genitor-urinary bleeding; CT of the head for intracranial bleeding). (See
         <a class="medical medical_review" href="/z/d/html/100310.html" rel="external">
          "Anticoagulant rodenticide poisoning: Clinical manifestations and diagnostic evaluation", section on 'Ancillary studies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H252303183">
         <span class="h2">
          Testing for synthetic cannabinoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rapid urine drug screens will
         <strong>
          not
         </strong>
         detect synthetic cannabinoids because the chemical compounds and their metabolites do not cross-react with delta-9 tetrahydrocannabinol (THC) or its metabolites, the agents that these screens are designed to detect [
         <a href="#rid59">
          59
         </a>
         ]. Confirmatory reference laboratory tests via liquid chromatography and mass spectrometry are available but do not return in a timely manner and will not help with immediate diagnosis or clinical care [
         <a href="#rid60">
          60-67
         </a>
         ]. However, identifying synthetic cannabinoids in blood or urine can have public health implications during outbreaks with significant clinical toxicities. If the original product is available, it can often be examined through forensic analytic laboratories with local authorities. However, because the chemical structures and compounds are constantly changing, they can still be difficult to identify, even for reference laboratories.
        </p>
        <p>
         Drug testing for cannabinoids in patients with acute cannabis (marijuana) intoxication is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/97099.html" rel="external">
          "Cannabis (marijuana): Acute intoxication", section on 'Drug testing for cannabinoids'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1084269965">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute intoxication with synthetic cannabinoids is a clinical diagnosis. It is typically made based upon a history of use of "spice," "fake," or "synthetic" marijuana (or various other names used for synthetic cannabinoids) obtained from the patient or bystanders, coupled with consistent physical findings. Although reference laboratory testing of the patient's urine or forensic testing of the product can provide confirmation of exposure, such studies are not readily available, do not impact clinical care, and are typically not performed. (See
         <a class="local">
          'Testing for synthetic cannabinoids'
         </a>
         above and
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1084269972">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with severe synthetic cannabinoid intoxication have features common to many other intoxications and medical conditions, especially those that cause agitation, status epilepticus, or acute psychosis :
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Agitation
         </strong>
         – It is important to assess for potentially dangerous organic causes of agitation as soon as this can be done safely  (
         <a class="graphic graphic_table graphicRef82146" href="/z/d/graphic/82146.html" rel="external">
          table 1
         </a>
         ). In the emergency department (ED), drug and alcohol intoxication or withdrawal are common diagnoses in combative adult and adolescent patients. A rapid serum glucose measurement (eg, fingerstick glucose), pulse oximetry, and a complete set of vital signs should be obtained in all patients. (See
         <a class="medical medical_review" href="/z/d/html/291.html" rel="external">
          "Assessment and emergency management of the acutely agitated or violent adult", section on 'Post-restraint medical evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6440.html" rel="external">
          "Emergency department approach to acute-onset psychosis in children", section on 'Approach'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/291.html" rel="external">
          "Assessment and emergency management of the acutely agitated or violent adult"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Known psychiatric illness is a risk factor for violent behavior, with schizophrenia (with and without paranoia), personality disorders, mania, and psychotic depression most often associated with violence. Psychosis, delirium, or dementia may lead to violent behavior. (See
         <a class="medical medical_review" href="/z/d/html/291.html" rel="external">
          "Assessment and emergency management of the acutely agitated or violent adult"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The mnemonic FIND ME (functional [ie, psychiatric], infectious, neurologic, drugs, metabolic, endocrine) may be helpful to organize a diagnostic search for the etiology of delirium and violence  (
         <a class="graphic graphic_table graphicRef59893" href="/z/d/graphic/59893.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4824.html" rel="external">
          "Diagnosis of delirium and confusional states"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Seizures
         </strong>
         – Toxicological causes of seizures are extensive and include but are not limited to the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sympathomimetics (see
         <a class="medical medical_review" href="/z/d/html/82952.html" rel="external">
          "Acute amphetamine and synthetic cathinone ("bath salt") intoxication", section on 'Central and peripheral nervous system'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cyclic antidepressants (see
         <a class="medical medical_review" href="/z/d/html/295.html" rel="external">
          "Tricyclic antidepressant poisoning", section on 'Clinical features'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Anticholinergic agents (eg, antihistamines) (see
         <a class="medical medical_review" href="/z/d/html/305.html" rel="external">
          "Anticholinergic poisoning", section on 'Clinical features of overdose'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          Isoniazid
         </a>
         (see
         <a class="medical medical_review" href="/z/d/html/316.html" rel="external">
          "Isoniazid (INH) poisoning", section on 'Clinical features of acute toxicity'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Methylxanthines (eg,
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         or caffeine) (see
         <a class="medical medical_review" href="/z/d/html/6501.html" rel="external">
          "Theophylline poisoning", section on 'Neurologic'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Organophosphates (see
         <a class="medical medical_review" href="/z/d/html/339.html" rel="external">
          "Organophosphate and carbamate poisoning", section on 'Acute toxicity'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Toxidromes (ie, physical findings characteristic for specific toxins) can be helpful for determining the cause of seizure for many of these agents, including sympathomimetics, anticholinergic agents, and organophosphates  (
         <a class="graphic graphic_table graphicRef71268" href="/z/d/graphic/71268.html" rel="external">
          table 3
         </a>
         ). In addition to anticholinergic findings, cyclic antidepressants will often cause a constellation of symptoms other than seizures, including central nervous system (CNS) depression, hypotension, and widened QRS on ECG. (See
         <a class="medical medical_review" href="/z/d/html/295.html" rel="external">
          "Tricyclic antidepressant poisoning", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some common medical causes of status epilepticus and differentiating features from synthetic cannabinoid intoxication include (see
         <a class="medical medical_review" href="/z/d/html/6222.html" rel="external">
          "Clinical features and complications of status epilepticus in children", section on 'Causes'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2217.html" rel="external">
          "Convulsive status epilepticus in adults: Classification, clinical features, and diagnosis", section on 'Etiology'
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypoglycemia – Low blood sugar (see
         <a class="medical medical_review" href="/z/d/html/5801.html" rel="external">
          "Causes of hypoglycemia in infants and children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1798.html" rel="external">
          "Hypoglycemia in adults without diabetes mellitus: Determining the etiology", section on 'Ill or medicated individuals'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Electrolyte imbalance (eg, hyponatremia or hypocalcemia) – Low serum sodium or calcium (see
         <a class="medical medical_review" href="/z/d/html/5846.html" rel="external">
          "Etiology of hypocalcemia in infants and children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2374.html" rel="external">
          "Causes of hypotonic hyponatremia in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/840.html" rel="external">
          "Etiology of hypocalcemia in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Central nervous system infection (eg, meningitis or encephalitis) – Fever and/or meningismus
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Intracranial mass lesion – Signs of increased intracranial pressure (eg, morning headache with vomiting, papilledema, and/or focal neurologic deficits)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Alcohol or sedative hypnotic withdrawal – Diaphoresis, agitation, tachycardia, hypertension, and a history of chronic ethanol consumption (see
         <a class="medical medical_review" href="/z/d/html/323.html" rel="external">
          "Management of moderate and severe alcohol withdrawal syndromes", section on 'Minor withdrawal symptoms'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/141183.html" rel="external">
          "Benzodiazepine withdrawal"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Traumatic brain injury (see
         <a class="medical medical_review" href="/z/d/html/6566.html" rel="external">
          "Severe traumatic brain injury (TBI) in children: Initial evaluation and management", section on 'Secondary survey'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute psychosis
         </strong>
         – The differential diagnosis and approach to acute psychosis in the emergency department is provided in the tables and algorithm  (
         <a class="graphic graphic_table graphicRef52785" href="/z/d/graphic/52785.html" rel="external">
          table 4
         </a>
         and
         <a class="graphic graphic_table graphicRef50275" href="/z/d/graphic/50275.html" rel="external">
          table 5
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef56663" href="/z/d/graphic/56663.html" rel="external">
          algorithm 1
         </a>
         ) and is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6440.html" rel="external">
          "Emergency department approach to acute-onset psychosis in children", section on 'Differential diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6440.html" rel="external">
          "Emergency department approach to acute-onset psychosis in children", section on 'Approach'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Differentiating synthetic cannabinoid toxicity from toxicity due to other drugs of abuse can be difficult. Mild synthetic cannabinoid toxicity can present in a fashion similar to that of natural cannabinoid toxicity. The difference will be a negative rapid drug screen for cannabis (marijuana) if the patient has not also used natural cannabinoids. Even if such urine drug screens are positive for agents such as cocaine or amphetamines, co-ingestion with synthetic cannabinoid may still exist. More severe synthetic cannabinoid intoxication can present in similar fashion to other sympathomimetics and hallucinogenics, including cocaine, amphetamines, lysergic acid diethylamide (LSD), phencyclidine (PCP), and other substances, such as "bath salts" (methcathinones) [
         <a href="#rid3">
          3-5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1084269979">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of synthetic cannabinoid intoxication is supportive and determined by the presence and severity of specific clinical manifestations.
        </p>
        <p class="headingAnchor" id="H252306714">
         <span class="h2">
          Mild to moderate intoxication
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mild to moderate intoxication with dysphoria can often be managed with a dimly lit room, reassurance, and decreased stimulation. Benzodiazepines (eg,
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         or
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         ) can be helpful in controlling symptoms of anxiety and have a low side effect profile.
        </p>
        <p class="headingAnchor" id="H252306963">
         <span class="h2">
          Severe intoxication
         </span>
         <span class="headingEndMark">
          —
         </span>
         Severe intoxication caused by synthetic cannabinoids can be life-threatening and warrants prompt treatment directed at the most significant findings.
        </p>
        <p class="headingAnchor" id="H1084269993">
         <span class="h3">
          Agitation and psychosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with severe agitation from synthetic cannabinoid intoxication usually do not respond to verbal de-escalation and require sedation with benzodiazepines (eg,
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         or
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         ) or other medications  (
         <a class="graphic graphic_algorithm graphicRef61852" href="/z/d/graphic/61852.html" rel="external">
          algorithm 2
         </a>
         ). Medical personnel should take precautions to protect themselves from violent behavior including a security presence and the application of physical restraints. (See
         <a class="medical medical_review" href="/z/d/html/291.html" rel="external">
          "Assessment and emergency management of the acutely agitated or violent adult", section on 'Management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6440.html" rel="external">
          "Emergency department approach to acute-onset psychosis in children", section on 'Patient and staff safety'
         </a>
         .)
        </p>
        <p>
         If intoxication leads to severe psychomotor agitation or hyperthermia, large doses of benzodiazepines may be needed for adequate sedation. Rarely,
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         infusions, intubation, paralysis, and/or external cooling may be indicated to prevent further end organ damage and development of rhabdomyolysis and acidosis [
         <a href="#rid28">
          28-32,43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H252307466">
         <span class="h3">
          Hyperthermia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperthermia (rectal temperature &gt;38.5°C [101°F]) may result from synthetic cannabinoid myotonic activity, seizures, rhabdomyolysis, or a combination of the three and should be managed aggressively with mechanical cooling measures.
        </p>
        <p>
         Augmentation of evaporative cooling is considered the treatment modality of choice because it is effective, noninvasive, and easily performed. The naked patient is sprayed with a mist of lukewarm water while air is circulated with large fans. Shivering may be suppressed with intravenous benzodiazepines, such as
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         (0.1 mg/kg, maximum single dose 5 mg IV) or
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         (0.05 to 0.1 mg/kg, maximum single dose 1 to 2 mg IV). Cold inspired oxygen, cold gastric lavage, cooling blankets, and cold intravenous fluids may be helpful adjuncts. (See
         <a class="medical medical_review" href="/z/d/html/176.html" rel="external">
          "Severe nonexertional hyperthermia (classic heat stroke) in adults", section on 'Cooling measures and temperature monitoring'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6596.html" rel="external">
          "Heat stroke in children", section on 'Rapid cooling'
         </a>
         .)
        </p>
        <p>
         Patients with marked agitation and hyperthermia (temperature &gt;40°C) who do not respond rapidly to initial pharmacologic interventions warrant rapid sequence intubation (RSI) followed by paralysis to stop heat generation from muscle activity  (
         <a class="graphic graphic_table graphicRef51456" href="/z/d/graphic/51456.html" rel="external">
          table 6
         </a>
         ). The clinician should
         <strong>
          avoid
         </strong>
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         when performing rapid sequence intubation if hyperkalemia due to rhabdomyolysis is present or highly suspected. (See
         <a class="medical medical_review" href="/z/d/html/270.html" rel="external">
          "Rapid sequence intubation in adults for emergency medicine and critical care"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/311.html" rel="external">
          "Methamphetamine: Acute intoxication", section on 'Hyperthermia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/82952.html" rel="external">
          "Acute amphetamine and synthetic cathinone ("bath salt") intoxication", section on 'Hyperthermia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/113029.html" rel="external">
          "Rapid sequence intubation (RSI) in children for emergency medicine: Medications for sedation and paralysis", section on 'Succinylcholine'
         </a>
         .)
        </p>
        <p>
         There is
         <strong>
          no role
         </strong>
         for antipyretic agents, such as
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         or
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , in the management of drug-induced hyperthermia since the underlying mechanism does not involve a change in the hypothalamic temperature set-point. Alcohol sponge baths should also be avoided because large amounts of alcohol may be absorbed through dilated cutaneous vessels and produce toxicity.
        </p>
        <p class="headingAnchor" id="H252307513">
         <span class="h3">
          Rhabdomyolysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperthermia, agitation, seizures, and muscle rigidity may lead to muscle cell breakdown (rhabdomyolysis) with significant risk for renal failure. Patients with rhabdomyolysis can present with the classic triad of pigmented granular casts in the urine, a red to brown color of the urine supernatant, and a marked elevation in serum creatine kinase (CK) although rhabdomyolysis may occur in patients whose urine shows no visually discernible color change. Primary treatment goals consist of (see
         <a class="medical medical_review" href="/z/d/html/14036.html" rel="external">
          "Prevention and treatment of heme pigment-induced acute kidney injury (including rhabdomyolysis)"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fluid repletion with isotonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         infusion (20 to 40 mL/kg per hour up to 1 to 2 L per hour); the emergency provider should closely monitor urine output with the goal of maintaining a minimum urine flow of 4 mL/kg per hour in children and 200 mL per hour in adults. Once diuresis is established with normal saline, alkalinization of the urine is commonly employed, but its efficacy is uncertain. (See
         <a class="medical medical_review" href="/z/d/html/14036.html" rel="external">
          "Prevention and treatment of heme pigment-induced acute kidney injury (including rhabdomyolysis)", section on 'Bicarbonate in selected patients'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation for significant electrolyte abnormalities (hyperkalemia, hyperphosphatemia, and hypocalcemia); management of hyperkalemia is of particular importance. Hypocalcemia is usually transient and calcium administration should be avoided unless severe symptoms (eg, tetany) are present.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H252306943">
         <span class="h3">
          Seizures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Seizures caused by synthetic cannabinoids warrant initial treatment with benzodiazepines (eg,
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         or
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         ), with repeat doses as necessary  (
         <a class="graphic graphic_table graphicRef55368" href="/z/d/graphic/55368.html" rel="external">
          table 7
         </a>
         ). If seizures are not controlled by appropriate doses of benzodiazepines, a second anticonvulsant agent such as
         <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">
          phenobarbital
         </a>
         should be administered. Antiepileptics whose mechanism of action relies on sodium channel blockade such as
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         or
         <a class="drug drug_general" data-topicid="8480" href="/z/d/drug information/8480.html" rel="external">
          fosphenytoin
         </a>
         are unlikely to be effective in toxin-induced seizures.
        </p>
        <p>
         Patients with seizures may warrant neuroimaging (eg, computed tomography [CT] of the brain) to evaluate for ischemic stroke, subarachnoid hemorrhage, or intracerebral hemorrhage if physical findings suggest a structural brain lesion (eg, focal neurologic findings) [
         <a href="#rid52">
          52,53
         </a>
         ].
        </p>
        <p>
         Although status epilepticus is unusual following synthetic cannabinoid intoxication, patients in status epilepticus should receive further pharmacologic therapy based upon the patient's hemodynamic status (eg, continuous infusions of
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         ,
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         , or
         <a class="drug drug_general" data-topicid="9754" href="/z/d/drug information/9754.html" rel="external">
          pentobarbital
         </a>
         )  (
         <a class="graphic graphic_algorithm graphicRef74649" href="/z/d/graphic/74649.html" rel="external">
          algorithm 3
         </a>
         ). The administration of
         <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">
          phenobarbital
         </a>
         after benzodiazepines often results in the need for airway protection with endotracheal intubation. (See
         <a class="medical medical_review" href="/z/d/html/6192.html" rel="external">
          "Management of convulsive status epilepticus in children", section on 'Refractory status epilepticus'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/132561.html" rel="external">
          "Refractory status epilepticus in adults", section on 'Definition and etiology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H616550235">
         <span class="h3">
          Chest pain
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chest pain in association with synthetic cannabinoid use should be managed according to etiology as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute coronary syndrome
         </strong>
         – Substernal squeezing chest pain suggestive of myocardial ischemia or infarction occurs rarely in association with synthetic cannabinoid use but has been described in older adolescents and young adults [
         <a href="#rid68">
          68,69
         </a>
         ]. Patients complaining of chest pain suggestive of coronary insufficiency should be evaluated for acute coronary syndrome and treated accordingly. (See
         <a class="medical medical_review" href="/z/d/html/184.html" rel="external">
          "Initial evaluation and management of suspected acute coronary syndrome (myocardial infarction, unstable angina) in the emergency department", section on 'Clinical presentation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/184.html" rel="external">
          "Initial evaluation and management of suspected acute coronary syndrome (myocardial infarction, unstable angina) in the emergency department", section on 'Management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Air leak
         </strong>
         – Inhalation and breathholding during synthetic cannabinoid use may cause a pneumothorax or pneumomediastinum with sharp, pleuritic chest pain and subcutaneous crepitus. Management of a pneumothorax depends upon its size and includes oxygen administration and, if necessary, evacuation of the air leak with needle decompression or chest tube insertion. (See
         <a class="medical medical_review" href="/z/d/html/6691.html" rel="external">
          "Treatment of secondary spontaneous pneumothorax in adults", section on 'Initial management of first event'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         No specific treatment is necessary for uncomplicated pneumomediastinum. (See
         <a class="medical medical_review" href="/z/d/html/6352.html" rel="external">
          "Spontaneous pneumomediastinum in children and adolescents", section on 'Management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Asthma exacerbation
         </strong>
         – Synthetic cannabinoid use may cause chest tightness with bronchospasm and wheezing. Standard therapy for status asthmaticus should be provided. (See
         <a class="medical medical_review" href="/z/d/html/528.html" rel="external">
          "Acute exacerbations of asthma in adults: Home and office management", section on 'Algorithms for assessment and treatment at home and in the office'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1084270007">
         <span class="h3">
          Acute kidney injury
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute kidney injury has been associated with use of one type of synthetic cannabinoid in a limited outbreak. Electrolytes and renal function should be measured in patients with severe intoxication, complaints of back pain, or urinary symptoms such as hematuria or oliguria. Biopsies of patients with acute kidney injury caused by synthetic cannabinoid use revealed histologic evidence for acute tubular necrosis [
         <a href="#rid54">
          54-57
         </a>
         ]. It is unclear whether the kidney injury was caused by direct toxicity, an unidentified nephrotoxin or contaminant, or patient predisposition. Treatment for acute kidney injury should be directed by the degree of renal dysfunction and related adverse effects such as hypertension, azotemia, and electrolyte abnormalities in consultation with a nephrologist. Most patients recover with supportive care. (See
         <a class="medical medical_review" href="/z/d/html/14035.html" rel="external">
          "Overview of the management of acute kidney injury (AKI) in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H467528996">
         <span class="h3">
          Stroke
         </span>
         <span class="headingEndMark">
          —
         </span>
         Synthetic cannabinoid use has been associated with ischemic and hemorrhagic stroke in case reports [
         <a href="#rid52">
          52,53
         </a>
         ]. Underlying vascular disease or other risk factors have
         <strong>
          not
         </strong>
         been described. These patients warrant consultation with a stroke specialist in addition to management for ischemic stroke or hemorrhagic stroke as described separately. (See
         <a class="medical medical_review" href="/z/d/html/1126.html" rel="external">
          "Initial assessment and management of acute stroke"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1084.html" rel="external">
          "Spontaneous intracerebral hemorrhage: Acute treatment and prognosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1111.html" rel="external">
          "Nonaneurysmal subarachnoid hemorrhage", section on 'Management and prognosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H252307318">
         <span class="h2">
          Dystonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest that patients with synthetic cannabinoid intoxication and dystonic reactions receive short-acting benzodiazepines (
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         and
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         ) instead of anticholinergic agents such as
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         . Although anticholinergic agents are useful in the treatment of many dystonic reactions, the antimuscarinic side effects have the potential to exacerbate agitation and delirium in patients with synthetic cannabinoid intoxication [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H499619498">
         <span class="h2">
          Life-threatening coagulopathy (brodifacoum adulteration)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with unexplained coagulopathy and/or bleeding and a history of recent synthetic cannabinoid use warrant screening for and treatment of brodifacoum poisoning in consultation with a regional poison control center. (See
         <a class="local">
          'Regional poison control centers'
         </a>
         below.)
        </p>
        <p>
         In 2018, there was an outbreak in Illinois involving more than 150 patients who developed coagulopathy and bleeding diathesis from adulteration of synthetic cannabinoids with brodifacoum (long-acting vitamin K antagonist rodenticide) [
         <a href="#rid58">
          58,70-72
         </a>
         ]. Similar events were described in Florida in 2021 and Israel in 2021 to 2022 [
         <a href="#rid73">
          73,74
         </a>
         ].
        </p>
        <p>
         The diagnosis and treatment of brodifacoum poisoning is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/100310.html" rel="external">
          "Anticoagulant rodenticide poisoning: Clinical manifestations and diagnostic evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/106877.html" rel="external">
          "Anticoagulant rodenticide poisoning: Management", section on 'Coagulopathy and active bleeding'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H190151023">
         <span class="h2">
          Gastrointestinal decontamination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because inhalation is the most popular route of exposure for synthetic cannabinoids and the onset of clinical effects is rapid and frequently includes altered mentation, there is no role for gastrointestinal decontamination for the treatment of synthetic cannabinoid intoxication, even in patients with oral ingestion.
        </p>
        <p class="headingAnchor" id="H1084270021">
         <span class="h1">
          DISPOSITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with mild to moderate symptoms of synthetic cannabinoid intoxication can usually be observed and treated in the emergency department until symptoms resolve (typically four to six hours). Screening for substance use disorder and underlying mental illness should also be performed once the patient is no longer intoxicated. (See
         <a class="medical medical_review" href="/z/d/html/7807.html" rel="external">
          "Substance use disorders: Clinical assessment"
         </a>
         .)
        </p>
        <p>
         Patients with severe agitation requiring large amounts of sedation, treatment of seizures, or management of significant complications of intoxication (eg, hyperthermia, rhabdomyolysis, myocardial ischemia, pneumothorax, or acute kidney injury) warrant hospital admission to an appropriate level of care based upon their clinical condition.
        </p>
        <p>
         The role of brief intervention for unhealthy drug use and indications for referral to substance abuse treatment are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14832.html" rel="external">
          "Brief intervention for unhealthy alcohol and other drug use: Efficacy, adverse effects, and administration"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7796.html" rel="external">
          "Cannabis use disorder: Clinical features, screening, diagnosis, and treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1084270028">
         <span class="h1">
          ADDITIONAL RESOURCES
         </span>
        </p>
        <p class="headingAnchor" id="H71013276">
         <span class="h2">
          Regional poison control centers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">
          "Society guideline links: Regional poison control centers"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3043779231">
         <span class="h2">
          Resources for substance use
         </span>
         <span class="headingEndMark">
          —
         </span>
         The Partnership for Drug Free Kids (www.Drugfree.org) maintains a
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdrugfree.org%2Fwp-content%2Fuploads%2F2017%2F02%2FDrug-Guide-for-Parents.pdf%3Fsearch-text%3Dmolly&amp;token=X4qBjtOh6QKLhBVWXrTyjlH%2BlNa4N%2FjjJ79sKrqFRKMxRejkTg8Y6ogffvTIIPPgArFNnZyOPeBwv%2FtqVP6rykMl5OI3CEGLnTIblE%2BquNW%2FSI%2B0vo%2FABYGsdNgDHcmc&amp;TOPIC_ID=97100" target="_blank">
          drug guide
         </a>
         for 40 commonly abused drugs including common slang terms.
        </p>
        <p>
         Resources specific for synthetic cannabinoids include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.emcdda.europa.eu%2Ftopics%2Fsynthetic-cannabinoids_en&amp;token=B%2BpBTebUKbbD7Evh96k4GVLPP0hKPf7JsDjSoQETHQxyu81CS%2BrMzYXryZmzx1V3rDmM%2BALZ2Ftiq44QtYoWGq8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=97100" target="_blank">
          European Monitoring Centre for Drugs and Drug Addiction: Synthetic cannabinoids
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fnida.nih.gov%2Fpublications%2Fdrugfacts%2Fsynthetic-cannabinoids-k2spice&amp;token=wFI70dZ1isjUXownydS6uwhyY9tKNaZLNNrYbKNVLEQMC1qiyOAc3EADjuiaauOk%2FIJPBXA2ovJx7%2BadqkeapsZGe8s9M2pZsJNIrP41w4c%3D&amp;TOPIC_ID=97100" target="_blank">
          National Institute of Drug Abuse (NIDA) Drug Facts: Synthetic cannabinoids (K2/Spice)
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fnceh%2Fhsb%2Fchemicals%2Fsc%2Fhealthcare.html&amp;token=mB0t5kGMJrv8oMcHlDr%2FBeWCt0azFmtOoMYxLPpTNX%2Fjh3iF5wzoXFtwABEi2jMcFXYX%2F5QRknKbUldmklW2qQ%3D%3D&amp;TOPIC_ID=97100" target="_blank">
          Synthetic cannabinoids: An overview for healthcare providers
         </a>
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H102316977">
         <span class="h2">
          Society guideline links
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112689.html" rel="external">
          "Society guideline links: General measures for acute poisoning treatment"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/114015.html" rel="external">
          "Society guideline links: Treatment of acute poisoning caused by recreational drug or alcohol use"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1084270035">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pharmacology
         </strong>
         – Synthetic cannabinoids are synthesized compounds used either as the chemical itself or added to herbs or other plants to appear as a natural product. They can be marketed as "incense" or "herbal remedies." They are sold under various names including: "K2," "spice," "crazy monkey," "chill out," "spice diamond," "spice gold," "chill X," or by their chemical nomenclature (eg, AMB-FUBINACA, JWH-018, CP 47, and many others). Synthetic cannabinoids are usually smoked or insufflated during recreational use. (See
         <a class="local">
          'Background'
         </a>
         above and
         <a class="local">
          'Toxicity and pharmacology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – Synthetic cannabinoids have a wide spectrum of clinical effects which can be similar to cannabis (marijuana) intoxication, such as tachycardia, conjunctival injection, nystagmus, vomiting, ataxia, and slurred speech. However, more serious toxicity has frequently occurred including severe psychomotor agitation, toxic psychosis, seizures, and coma. Agitation has been complicated by hyperthermia and rhabdomyolysis. Rarely, acute kidney injury, myocardial infarction, ischemic stroke, subarachnoid hemorrhage, and death have been reported. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ancillary studies
         </strong>
         – For most mild or moderate intoxications, no ancillary studies are needed. All patients with marked agitation or seizures should have a rapid serum glucose measurement (eg, fingerstick glucose). Additional testing may also be indicated based upon clinical features. Rapid urine drug screens will
         <strong>
          not
         </strong>
         detect synthetic cannabinoids. (See
         <a class="local">
          'Ancillary studies'
         </a>
         above and
         <a class="local">
          'Testing for synthetic cannabinoids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – Acute intoxication with synthetic cannabinoids is a clinical diagnosis that is typically made based upon a history of "K2," "Spice," or "fake"/"synthetic" marijuana use obtained from the patient or bystanders with consistent physical findings. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – Patients with severe synthetic cannabinoid intoxication often have features common to many other intoxications and medical conditions, especially those that cause agitation, status epilepticus, or acute psychosis. Other evaluation is indicated based upon the primary presenting symptoms and possible diagnoses. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – The management of synthetic cannabinoid intoxication is supportive and determined by the presence and severity of specific clinical manifestations (see
         <a class="local">
          'Management'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mild to moderate intoxication
         </strong>
         – Symptoms such as dysphoria can often be managed with a dimly lit room, reassurance, and decreased stimulation. Benzodiazepines (eg,
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         or
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         ) can be helpful in controlling symptoms of anxiety and have a low side effect profile. (See
         <a class="local">
          'Mild to moderate intoxication'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Severe intoxication
         </strong>
         – Severe intoxication caused by synthetic cannabinoids can be life-threatening and warrants prompt treatment directed at the most significant findings (see
         <a class="local">
          'Severe intoxication'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Patients with severe agitation from synthetic cannabinoid intoxication usually do not respond to verbal de-escalation and require sedation with benzodiazepines (eg,
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         or
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         ) or other medications  (
         <a class="graphic graphic_algorithm graphicRef61852" href="/z/d/graphic/61852.html" rel="external">
          algorithm 2
         </a>
         ). Medical personnel should take precautions to protect themselves from violent behavior including a security presence and the application of physical restraints. (See
         <a class="local">
          'Agitation and psychosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Hyperthermia (rectal temperature &gt;38.5°C [101°F]) may result from synthetic cannabinoid myotonic activity, seizures, rhabdomyolysis, or a combination of the three and should be managed aggressively with mechanical cooling measures. (See
         <a class="local">
          'Hyperthermia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Seizures caused by synthetic cannabinoid warrant initial treatment with benzodiazepines (eg,
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         or
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         ) with repeat doses as necessary  (
         <a class="graphic graphic_table graphicRef55368" href="/z/d/graphic/55368.html" rel="external">
          table 7
         </a>
         ). If seizures are not controlled by appropriate doses of benzodiazepines, a second anticonvulsant agent such as
         <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">
          phenobarbital
         </a>
         should be administered. The administration of phenobarbital after benzodiazepines often results in the need for airway protection with endotracheal intubation and mechanical ventilation. (See
         <a class="local">
          'Seizures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Chest pain in association with cannabis use should be managed according to etiology (eg, myocardial ischemia versus pneumomediastinum or pneumothorax). (See
         <a class="local">
          'Chest pain'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Acute kidney injury has been associated with use of one type of synthetic cannabinoid in a limited outbreak but may also complicate rhabdomyolysis from severe psychomotor agitation. Treatment for acute kidney injury should be directed by the degree of renal dysfunction and related adverse effects such as hypertension, azotemia, and electrolyte abnormalities in consultation with a nephrologist. (See
         <a class="local">
          'Acute kidney injury'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Dystonia
         </strong>
         – In a patient with a dystonic reaction in the setting of synthetic cannabinoid intoxication, we suggest treatment with benzodiazepines (eg,
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         or
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         ) instead of anticholinergic agents (eg,
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         ) to avoid exacerbation of hyperthermia (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Dystonia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1858543029">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Stephen J Traub, MD, former section editor of the toxicology program, for 20 years of dedicated service.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Understanding the Spice Phenomenon. European Monitoring Centre for Drugs and Drug Addiction. http://www.emcdda.europa.eu/attachements.cfm/att_80086_EN_Spice%20Thematic%20paper%20—%20final%20version.pdf (Accessed on July 01, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: temporary placement of four synthetic cannabinoids into Schedule I. Final order. Fed Regist 2014; 79:7577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Musselman ME, Hampton JP. "Not for human consumption": a review of emerging designer drugs. Pharmacotherapy 2014; 34:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson ME, Bryant SM, Aks SE. Emerging drugs of abuse. Emerg Med Clin North Am 2014; 32:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenbaum CD, Carreiro SP, Babu KM. Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. J Med Toxicol 2012; 8:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wells DL, Ott CA. The "new" marijuana. Ann Pharmacother 2011; 45:414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashton JC. Synthetic cannabinoids as drugs of abuse. Curr Drug Abuse Rev 2012; 5:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monti MC, Zeugin J, Koch K, et al. Adulteration of low-delta-9-tetrahydrocannabinol products with synthetic cannabinoids: Results from drug checking services. Drug Test Anal 2022; 14:1026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuehn B. Synthetic Cannabidiol Poisoning. JAMA 2018; 319:2264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Potts AJ, Cano C, Thomas SHL, Hill SL. Synthetic cannabinoid receptor agonists: classification and nomenclature. Clin Toxicol (Phila) 2020; 58:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pulver B, Fischmann S, Gallegos A, Christie R. EMCDDA framework and practical guidance for naming synthetic cannabinoids. Drug Test Anal 2023; 15:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams AJ, Banister SD, Irizarry L, et al. "Zombie" Outbreak Caused by the Synthetic Cannabinoid AMB-FUBINACA in New York. N Engl J Med 2017; 376:235.
          </a>
         </li>
         <li class="breakAll">
          European Monitoring Centre for Drugs and Drug Addiction. European Drug Report: Trends and Developments (2022). https://www.emcdda.europa.eu/system/files/publications/14644/TDAT22001ENN.pdf.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trecki J, Gerona RR, Schwartz MD. Synthetic Cannabinoid-Related Illnesses and Deaths. N Engl J Med 2015; 373:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Law R, Schier J, Martin C, et al. Notes from the Field: Increase in Reported Adverse Health Effects Related to Synthetic Cannabinoid Use - United States, January-May 2015. MMWR Morb Mortal Wkly Rep 2015; 64:618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoyte CO, Jacob J, Monte AA, et al. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med 2012; 60:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wood KE. Exposure to bath salts and synthetic tetrahydrocannabinol from 2009 to 2012 in the United States. J Pediatr 2013; 163:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monte AA, Bronstein AC, Cao DJ, et al. An outbreak of exposure to a novel synthetic cannabinoid. N Engl J Med 2014; 370:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasper AM, Ridpath AD, Arnold JK, et al. Severe Illness Associated with Reported Use of Synthetic Cannabinoids - Mississippi, April 2015. MMWR Morb Mortal Wkly Rep 2015; 64:1121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kemp AM, Clark MS, Dobbs T, et al. Top 10 Facts You Need to Know About Synthetic Cannabinoids: Not So Nice Spice. Am J Med 2016; 129:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Springer YP, Gerona R, Scheunemann E, et al. Increase in Adverse Reactions Associated with Use of Synthetic Cannabinoids - Anchorage, Alaska, 2015-2016. MMWR Morb Mortal Wkly Rep 2016; 65:1108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasper AM, Ridpath AD, Gerona RR, et al. Severe illness associated with reported use of synthetic cannabinoids: a public health investigation (Mississippi, 2015). Clin Toxicol (Phila) 2019; 57:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein TA, Dilley JA, Graves JM, Liebelt EL. Synthetic cannabinoid poisonings and access to the legal cannabis market: findings from US national poison centre data 2016-2019. Clin Toxicol (Phila) 2022; 60:1024.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crulli B, Dines AM, Blanco G, et al. Novel psychoactive substances-related presentations to the emergency departments of the European drug emergencies network plus (Euro-DEN plus) over the six-year period 2014-2019. Clin Toxicol (Phila) 2022; 60:1318.
          </a>
         </li>
         <li class="breakAll">
          European Monitoring Centre for Drugs and Drug Addiction. Synthetic cannabinoids. https://www.emcdda.europa.eu/topics/synthetic-cannabinoids_en.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palamar JJ, Barratt MJ, Coney L, Martins SS. Synthetic Cannabinoid Use Among High School Seniors. Pediatrics 2017; 140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riederer AM, Campleman SL, Carlson RG, et al. Acute Poisonings from Synthetic Cannabinoids - 50 U.S. Toxicology Investigators Consortium Registry Sites, 2010-2015. MMWR Morb Mortal Wkly Rep 2016; 65:692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen J, Morrison S, Greenberg J, Saidinejad M. Clinical presentation of intoxication due to synthetic cannabinoids. Pediatrics 2012; 129:e1064.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris CR, Brown A. Synthetic cannabinoid intoxication: a case series and review. J Emerg Med 2013; 44:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hermanns-Clausen M, Kneisel S, Szabo B, Auwärter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 2013; 108:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lapoint J, James LP, Moran CL, et al. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol (Phila) 2011; 49:760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winstock AR, Barratt MJ. The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Hum Psychopharmacol 2013; 28:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohr ALA, Logan BK, Fogarty MF, et al. Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017-2020: A Review. J Anal Toxicol 2022; 46:e116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Auwärter V, Dresen S, Weinmann W, et al. 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 2009; 44:832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ammann J, McLaren JM, Gerostamoulos D, Beyer J. Detection and quantification of new designer drugs in human blood: Part 1 - Synthetic cannabinoids. J Anal Toxicol 2012; 36:372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity? Life Sci 2014; 97:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajasekaran M, Brents LK, Franks LN, et al. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicol Appl Pharmacol 2013; 269:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hindson SA, Andrews RC, Danson MJ, et al. Synthetic cannabinoid receptor agonists are monoamine oxidase-A selective inhibitors. FEBS J 2023; 290:3243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dresen S, Ferreirós N, Pütz M, et al. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J Mass Spectrom 2010; 45:1186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King A, Hill SL, Pucci M, et al. Clinical features associated with ADB-BUTINACA exposure in patients attending emergency departments in England. Clin Toxicol (Phila) 2022; 60:1094.
          </a>
         </li>
         <li class="breakAll">
          European Monitoring Centre for Drugs and Drug Addiction. Synthetic cannabinoids drug profile. https://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cannabinoids_en.
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Petrocellis L, Melck D, Bisogno T, Di Marzo V. Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chem Phys Lipids 2000; 108:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kronstrand R, Roman M, Andersson M, Eklund A. Toxicological findings of synthetic cannabinoids in recreational users. J Anal Toxicol 2013; 37:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson SAR, Oprescu AM, Calello DP, et al. Neuropsychiatric Sequelae in Adolescents With Acute Synthetic Cannabinoid Toxicity. Pediatrics 2019; 144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seywright A, Torrance HJ, Wylie FM, et al. Analysis and clinical findings of cases positive for the novel synthetic cannabinoid receptor agonist MDMB-CHMICA. Clin Toxicol (Phila) 2016; 54:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill SL, Najafi J, Dunn M, et al. Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study. Clin Toxicol (Phila) 2016; 54:638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shopan N, Scolnik D, Hassoun E, et al. Acute intoxication caused by three common synthetic cannabinoids: The experience of a large, urban, tertiary care hospital. Am J Emerg Med 2023; 73:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruiz-Maldonado TM, Dorey A, Christensen ED, Campbell KA. Near-Fatal Spice Intoxication of a Toddler. Pediatrics 2021; 148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mir A, Obafemi A, Young A, Kane C. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 2011; 128:e1622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young AC, Schwarz E, Medina G, et al. Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am J Emerg Med 2012; 30:1320.e5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark BC, Georgekutty J, Berul CI. Myocardial Ischemia Secondary to Synthetic Cannabinoid (K2) Use in Pediatric Patients. J Pediatr 2015; 167:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rose DZ, Guerrero WR, Mokin MV, et al. Hemorrhagic stroke following use of the synthetic marijuana "spice". Neurology 2015; 85:1177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freeman MJ, Rose DZ, Myers MA, et al. Ischemic stroke after use of the synthetic marijuana "spice". Neurology 2013; 81:2090.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhanushali GK, Jain G, Fatima H, et al. AKI associated with synthetic cannabinoids: a case series. Clin J Am Soc Nephrol 2013; 8:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Acute kidney injury associated with synthetic cannabinoid use--multiple states, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thornton SL, Wood C, Friesen MW, Gerona RR. Synthetic cannabinoid use associated with acute kidney injury. Clin Toxicol (Phila) 2013; 51:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buser GL, Gerona RR, Horowitz BZ, et al. Acute kidney injury associated with smoking synthetic cannabinoid. Clin Toxicol (Phila) 2014; 52:664.
          </a>
         </li>
         <li class="breakAll">
          Outbreak alert: Potential life-threatening vitamin K-dependent antagonist coagulopathy associated with synthetic cannabinoids use. Centers for Disease Control and Prevention. April 5, 2018. https://content.govdelivery.com/accounts/USCDC/bulletins/1e6dac3.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arntson A, Ofsa B, Lancaster D, et al. Validation of a novel immunoassay for the detection of synthetic cannabinoids and metabolites in urine specimens. J Anal Toxicol 2013; 37:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hutter M, Broecker S, Kneisel S, Auwärter V. Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in 'herbal mixtures' using LC-MS/MS techniques. J Mass Spectrom 2012; 47:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran CL, Le VH, Chimalakonda KC, et al. Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal Chem 2011; 83:4228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Penn HJ, Langman LJ, Unold D, et al. Detection of synthetic cannabinoids in herbal incense products. Clin Biochem 2011; 44:1163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobolevsky T, Prasolov I, Rodchenkov G. Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Sci Int 2010; 200:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freijo TD Jr, Harris SE, Kala SV. A rapid quantitative method for the analysis of synthetic cannabinoids by liquid chromatography-tandem mass spectrometry. J Anal Toxicol 2014; 38:466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giorgetti A, Barone R, Pelletti G, et al. Development and validation of a rapid LC-MS/MS method for the detection of 182 novel psychoactive substances in whole blood. Drug Test Anal 2022; 14:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Namera A, Kawamura M, Nakamoto A, et al. Comprehensive review of the detection methods for synthetic cannabinoids and cathinones. Forensic Toxicol 2015; 33:175.
          </a>
         </li>
         <li class="breakAll">
          United Nations Office on Drugs and Crime. Recommended methods for the identification and analysis of synthetic cannabinoid receptor agonists in seized materials. https://www.unodc.org/documents/scientific/STNAR48_Synthetic_Cannabinoids_ENG.pdf.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caldicott DG, Holmes J, Roberts-Thomson KC, Mahar L. Keep off the grass: marijuana use and acute cardiovascular events. Eur J Emerg Med 2005; 12:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deharo P, Massoure PL, Fourcade L. Exercise-induced acute coronary syndrome in a 24-year-old man with massive cannabis consumption. Acta Cardiol 2013; 68:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moritz E, Austin C, Wahl M, et al. Notes from the Field: Outbreak of Severe Illness Linked to the Vitamin K Antagonist Brodifacoum and Use of Synthetic Cannabinoids - Illinois, March-April 2018. MMWR Morb Mortal Wkly Rep 2018; 67:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelkar AH, Smith NA, Martial A, et al. An Outbreak of Synthetic Cannabinoid-Associated Coagulopathy in Illinois. N Engl J Med 2018; 379:1216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connors JM. Hemorrhagic Highs from Synthetic Cannabinoids - A New Epidemic. N Engl J Med 2018; 379:1275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coble N, Mulay P, Funk A, et al. Notes from the Field: Coagulopathy Associated with Brodifacoum Poisoning - Florida, December 2021. MMWR Morb Mortal Wkly Rep 2022; 71:1288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lurie Y, Nadir Y, Hoffman R, et al. An outbreak of severe coagulopathy in northern Israel among users of illicit synthetic cannabinoids adulterated with brodifacoum. Clin Toxicol (Phila) 2023; 61:429.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 97100 Version 43.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="http://www.emcdda.europa.eu/attachements.cfm/att_80086_EN_Spice%20Thematic%20paper%20" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Understanding the Spice Phenomenon. European Monitoring Centre for Drugs and Drug Addiction. http://www.emcdda.europa.eu/attachements.cfm/att_80086_EN_Spice%20Thematic%20paper%20—%20final%20version.pdf (Accessed on July 01, 2014).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24605391" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Schedules of controlled substances: temporary placement of four synthetic cannabinoids into Schedule I. Final order.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24710806" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : "Not for human consumption": a review of emerging designer drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24275167" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Emerging drugs of abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22271566" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21325097" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The "new" marijuana.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22530798" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Synthetic cannabinoids as drugs of abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34997693" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Adulteration of low-delta-9-tetrahydrocannabinol products with synthetic cannabinoids: Results from drug checking services.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29896635" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Synthetic Cannabidiol Poisoning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31524007" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Synthetic cannabinoid receptor agonists: classification and nomenclature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36346325" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : EMCDDA framework and practical guidance for naming synthetic cannabinoids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27973993" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : "Zombie" Outbreak Caused by the Synthetic Cannabinoid AMB-FUBINACA in New York.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27973993" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : "Zombie" Outbreak Caused by the Synthetic Cannabinoid AMB-FUBINACA in New York.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26154784" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Synthetic Cannabinoid-Related Illnesses and Deaths.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26068566" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Notes from the Field: Increase in Reported Adverse Health Effects Related to Synthetic Cannabinoid Use - United States, January-May 2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22575211" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23391041" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Exposure to bath salts and synthetic tetrahydrocannabinol from 2009 to 2012 in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24450915" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : An outbreak of exposure to a novel synthetic cannabinoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26447715" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Severe Illness Associated with Reported Use of Synthetic Cannabinoids - Mississippi, April 2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26522795" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Top 10 Facts You Need to Know About Synthetic Cannabinoids: Not So Nice Spice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27736839" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Increase in Adverse Reactions Associated with Use of Synthetic Cannabinoids - Anchorage, Alaska, 2015-2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29989463" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Severe illness associated with reported use of synthetic cannabinoids: a public health investigation (Mississippi, 2015).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35942512" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Synthetic cannabinoid poisonings and access to the legal cannabis market: findings from US national poison centre data 2016-2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36322684" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Novel psychoactive substances-related presentations to the emergency departments of the European drug emergencies network plus (Euro-DEN plus) over the six-year period 2014-2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36322684" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Novel psychoactive substances-related presentations to the emergency departments of the European drug emergencies network plus (Euro-DEN plus) over the six-year period 2014-2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28893851" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Synthetic Cannabinoid Use Among High School Seniors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27413997" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Acute Poisonings from Synthetic Cannabinoids - 50 U.S. Toxicology Investigators Consortium Registry Sites, 2010-2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22430444" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Clinical presentation of intoxication due to synthetic cannabinoids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22989695" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Synthetic cannabinoid intoxication: a case series and review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22971158" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21970775" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Severe toxicity following synthetic cannabinoid ingestion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23881887" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35445267" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017-2020: A Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19189348" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22593567" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Detection and quantification of new designer drugs in human blood: Part 1 - Synthetic cannabinoids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24084047" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared toΔ(9)-THC: mechanism underlying greater toxicity?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23537664" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36708234" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Synthetic cannabinoid receptor agonists are monoamine oxidase-A selective inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20857386" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35943421" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Clinical features associated with ADB-BUTINACA exposure in patients attending emergency departments in England.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35943421" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Clinical features associated with ADB-BUTINACA exposure in patients attending emergency departments in England.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11106791" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23970540" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Toxicological findings of synthetic cannabinoids in recreational users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31285395" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Neuropsychiatric Sequelae in Adolescents With Acute Synthetic Cannabinoid Toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27213960" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Analysis and clinical findings of cases positive for the novel synthetic cannabinoid receptor agonist MDMB-CHMICA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27251903" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37572408" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Acute intoxication caused by three common synthetic cannabinoids: The experience of a large, urban, tertiary care hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34233919" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Near-Fatal Spice Intoxication of a Toddler.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22065271" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Myocardial infarction associated with use of the synthetic cannabinoid K2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21802885" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26165442" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Myocardial Ischemia Secondary to Synthetic Cannabinoid (K2) Use in Pediatric Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26320200" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Hemorrhagic stroke following use of the synthetic marijuana "spice".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24212384" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Ischemic stroke after use of the synthetic marijuana "spice".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23243266" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : AKI associated with synthetic cannabinoids: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23407124" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Acute kidney injury associated with synthetic cannabinoid use--multiple states, 2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23473465" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Synthetic cannabinoid use associated with acute kidney injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25089722" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Acute kidney injury associated with smoking synthetic cannabinoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25089722" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Acute kidney injury associated with smoking synthetic cannabinoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23625703" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Validation of a novel immunoassay for the detection of synthetic cannabinoids and metabolites in urine specimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22282090" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in 'herbal mixtures' using LC-MS/MS techniques.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21506519" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21741374" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Detection of synthetic cannabinoids in herbal incense products.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20430547" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Detection of JWH-018 metabolites in smoking mixture post-administration urine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25217534" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : A rapid quantitative method for the analysis of synthetic cannabinoids by liquid chromatography-tandem mass spectrometry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34599648" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Development and validation of a rapid LC-MS/MS method for the detection of 182 novel psychoactive substances in whole blood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26257831" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Comprehensive review of the detection methods for synthetic cannabinoids and cathinones.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26257831" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Comprehensive review of the detection methods for synthetic cannabinoids and cathinones.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16175062" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Keep off the grass: marijuana use and acute cardiovascular events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24187771" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Exercise-induced acute coronary syndrome in a 24-year-old man with massive cannabis consumption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29851941" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Notes from the Field: Outbreak of Severe Illness Linked to the Vitamin K Antagonist Brodifacoum and Use of Synthetic Cannabinoids - Illinois, March-April 2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30280655" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : An Outbreak of Synthetic Cannabinoid-Associated Coagulopathy in Illinois.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30257159" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Hemorrhagic Highs from Synthetic Cannabinoids - A New Epidemic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36201387" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Notes from the Field: Coagulopathy Associated with Brodifacoum Poisoning - Florida, December 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37293741" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : An outbreak of severe coagulopathy in northern Israel among users of illicit synthetic cannabinoids adulterated with brodifacoum.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
